Metraipolis › archive › dc_f6d281ccbb55
Efficacy and safety of iguratimod in patients with primary Sjögren's syndrome: a multicentre randomised controlled trial — Europe PMC PMID:41423293
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41423293
- DOI
- 10.1136/rmdopen-2025-006180
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T12:04:04.517Z
- SHA-256 of the archived text
66cf8da628cb97f0ab971223c182b9b6d34b59e404ef84a736f3af014f8b4925- Stable URL of this page
https://metraipolis.com/documento/dc_f6d281ccbb55
How to cite
Efficacy and safety of iguratimod in patients with primary Sjögren's syndrome: a multicentre randomised controlled trial — Europe PMC PMID:41423293 — Europe PMC (en), https://europepmc.org/article/MED/41423293 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f6d281ccbb55 (Metraipolis archive dc_f6d281ccbb55, sha256 66cf8da628cb97f0ab971223c182b9b6d34b59e404ef84a736f3af014f8b4925)
BibTeX
@misc{dcf6d281ccbb55,
title = {Efficacy and safety of iguratimod in patients with primary Sjögren's syndrome: a multicentre randomised controlled trial — Europe PMC PMID:41423293},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41423293},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f6d281ccbb55; sha256 66cf8da628cb97f0ab971223c182b9b6d34b59e404ef84a736f3af014f8b4925},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41423293. Agents can read the archived copy with the MCP tool read_document.